Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's expansion in MG and CIDP, including the new seronegative MG approval. Strong pipeline progress and disciplined capital allocation support long-term growth, with multiple late-stage readouts expected this year.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.